Predict your next investment

cellvie company logo
HEALTHCARE | Biotechnology

See what CB Insights has to offer

Founded Year



Seed VC | Alive

Total Raised


Last Raised

$5M | 8 mos ago

About cellvie

cellvie develops cell-derived medicines, leveraging the therapeutic potential of mitochondria.

cellvie Headquarter Location

Speditionstrasse 15a

Dusseldorf, 40221,


Latest cellvie News

Swiss-US biotech secures 5 million USD to advance pipeline

Jan 29, 2021

Cellvie is a Harvard spin-off founded in the US with headquarters in Zurich. The company is developing medicines from cells, leveraging the therapeutic potential of mitochondria. The company has closed a $5M round to prepare a clinical trial in organ transplantation and to expand cellvie’s pipeline into rejuvenation therapies. Cellvie , a leader in Therapeutic Mitochondria Transfer (TMT), was founded by James McCully, Alexander Schueller (CEO), Pedro del Nido and Sitaram Emani in 2018. Mitochondria are the powerhouses of the cell, generating most of the cellular energy and operate as critical intra-cellular communication nodes. Mitochondria dysfunction has been tied to a host of diseases, ranging from neurodegenerative ailments such as Parkinson’s and Alzheimer’s, over heart attacks and strokes, to age-related degeneration. “But treating mitochondria has proven to be an arduous challenge,” said James McCully, founder of cellvie and Associate Professor of Surgery at Boston’s Children’s Hospital and Harvard Medical School. “That is why we turned to introduce healthy, viable mitochondria into cells where these organelles are impaired. To great effect. We can sustainably reinvigorate cells’ failing energy metabolism.”  McCully pioneered the approach of mitochondria augmentation and replacement at Harvard Medical School. The team has now set out to bring it about as a new treatment modality in ischemia-reperfusion injury (IRI), ageing, and beyond. IRI is of the world’s leading causes of death. IRI manifests itself whenever the blood flow to a part of the body is interrupted and subsequently reintroduced. Well-known medical conditions include heart attacks, strokes, and organ transplantation. The potential of Therapeutic Mitochondria Transfer was recently demonstrated in a clinical investigation at Boston Children’s Hospital. Pediatric patients on heart-lung-support after suffering a cardiogenic shock received the treatment to revitalize their heart muscle. 80% of these children experienced myocardial recovery, which compares to an expected 29%, as reported in a publication forthcoming in The Journal of Thoracic and Cardiovascular Surgery. Cellvie is pursuing an indication in organ transplantation, first, for which the FDA awarded orphan drug designation in 2020. The company has completed a new financing round raising $ 5 million, with Kizoo Technology Capital as the lead investor. The capital injection will be employed for productization, to expand cellvie’s product pipeline and to prepare an IND submission for a clinical study in kidney transplantation. (Press release)

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing cellvie

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

cellvie is included in 2 Expert Collections, including Biopharmaceuticals.



5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Regenerative Medicine

1,763 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.